Catalyst
Slingshot members are tracking this event:
Aimmune (AIMT) Will Begin Enrollment for RAMSES Trial Designed to Build Real-World Experience with AR101 in Desensitization of Peanut Allergies in the Q2 2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| AIMT |
|
|
||||
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
May 11, 2017
Occurred Source:
http://ir.aimmune.com/phoenix.zhtml?c=254097&p=irol-pressReleasesArticle&ID=2272234
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Ramses Trial, Real-world Experience, Ar101, Peanut Allergies, Desensitization Of Peanut Allergies
